Caitlin T. Fierheller

Caitlin T. Fierheller

Auto-generated profile, based on publicly available information

Caitlin T. Fierheller

Wolfson Institute of Population Health, Queen Mary University of London, London EC1M 6BQ, UK

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 March 2024 in Cancers
Verified
Journal Article
Open access
PDF file
SOSamuel Oxley
Samuel Oxley
XWXia Wei
Xia Wei
Michail SiderisMichail Sideris
Michail Sideris
OBOleg Blyuss
Oleg Blyuss
AKAshwin Kalra
Ashwin Kalra
RLRosa Legood
Rosa Legood
Background: Risk-reducing mastectomy (RRM) and risk-reducing salpingo-oophorectomy (RRSO) are the most effective breast and ovarian cancer preventive interventions. EQ-5D is the recommended tool to assess the quality of life and determine health-related utility scores (HRUSs), yet there are no published EQ-5D HRUSs after these procedures. These are essential for clinicians counselling patients and for health-economic evaluations. Methods: We used aggregate data from our published systematic review and converted SF-36/SF-12 summary scores to EQ-5D HRUSs using a published mapping algorithm. Study control arm or age-matched country-specific reference values provided comparison. Random-effects meta-analysis provided adjusted disutilities and utility scores. Subgroup analyses included long-term vs. short-term follow-up. Results: Four studies (209 patients) reported RRM outcomes using SF-36, and five studies (742 patients) reported RRSO outcomes using SF-12/SF-36. RRM is associated with a long-term (>2 years) disutility of −0.08 (95% CI −0.11, −0.04) (I2 31.4%) and a utility of 0.92 (95% CI 0.88, 0.95) (I2 31.4%). RRSO is associated with a long-term (>1 year) disutility of −0.03 (95% CI −0.05, 0.00) (I2 17.2%) and a utility of 0.97 (95% CI 0.94, 0.99) (I2 34.0%). Conclusions: We present the first HRUSs sourced from patients following RRM and RRSO. There is a need for high-quality prospective studies to characterise quality of life at different timepoints.

24 October 2025 in Cancers
Verified
Journal Article
Open access
PDF file
Michail SiderisMichail Sideris
Michail Sideris
Mark BrincatMark Brincat
Mark Brincat
OBOleg Blyuss
Oleg Blyuss
SOSamuel Oxley
Samuel Oxley
JSJacqueline Sia
Jacqueline Sia
Ranjit ManchandaRanjit Manchanda
Ranjit Manchanda
Objective: The P-POSSUM scale is widely used in predicting perioperative morbidity and mortality. Evidence on the performance of P-POSSUM in predicting outcomes after cytoreductive surgery (CRS) for ovarian cancer (OC) is limited. In this study, we assess how well P-POSSUM predicts morbidity in OC CRS and explore whether incorporating additional clinical variables can enhance its predictive accuracy. We retrospectively collected data on consecutive patients undergoing OC CRS within a tertiary gynaecologic oncology network. The collected information included demographic characteristics, P-POSSUM morbidity and mortality scores, Edmonton Frail Scale (EFS) scores, preoperative serum albumin levels, and observed 30-day postoperative morbidity and mortality, classified using the Clavien–Dindo (CD) scale. The predictive performance of P-POSSUM was evaluated using receiver operating characteristic (ROC) curves to calculate sensitivity and specificity. A stepwise regression analysis was then applied to identify additional variables that could improve model performance, incorporating preoperative covariates. The final model incorporated parameters chosen through bootstrap investigation of the model variability (stepAIC). Predicted versus observed morbidity was calibrated and performance compared between P-POSSUM and the final model. Results: Of 161 sequential OC patients, 95 (59%) underwent primary, 45 (28%) interval, and 21 (13%) delayed CRS. The mean age was 66.4 (95%CI: 60–75) and duration of surgery was 223 mins (95%CI: 142–279). Sixty-five (40.3%) patients had ≥1 postoperative complication. Two deaths were reported. Among the observed complications, 4 patients (6.1%) experienced CD4, 10 patients (15.3%) CD3, 38 patients (58.5%) CD2, and 11 patients (16.9%) CD1 events. The mean P-POSSUM-predicted morbidity and mortality were 59.5% (95%CI: 56.7–62.3%) and 5.86% (95%CI: 5.02–6.70%), respectively. The area under the curve (AUC) for P-POSSUM in predicting morbidity and mortality was 0.539 (p = 0.401) and 0.569 (p = 0.137), respectively. Given the small number of deaths, no robust conclusions regarding mortality are possible. EFS and BMI emerged as significant predictors of observed morbidity using a stepwise-model selection process. The AIC of this final model was 211.44. Our final model of PPOSSUM + EFS + BMI had AUC = 0.6551 (Delong’s Z = 1.8845, p-value = 0.05949). Conclusions: The P-POSSUM scale shows poor performance for predicting morbidity in OC CRS. New validated and accurate model(s) are necessary for predicting surgical morbidity. Our proposed model incorporates additional variables to improve P-POSSUM’s performance. This requires further development and validation.

25 June 2024 in Cancers
Verified
Journal Article
Open access
PDF file
TGTamar A. Gootzen
Tamar A. Gootzen
AKAshwin Kalra
Ashwin Kalra
KSKatrina Sarig
Katrina Sarig
Monika SobocanMonika Sobocan
Monika Sobocan
SOSamuel Oxley
Samuel Oxley
Ranjit ManchandaRanjit Manchanda
Ranjit Manchanda
BRCA genetic testing is available for UK Jewish individuals but the provision of information online for BRCA is unknown. We aimed to evaluate online provision of BRCA information by UK organisations (UKO), UK Jewish community organisations (JCO), and genetic testing providers (GTP). Google searches for organisations offering BRCA information were performed using relevant sets of keywords. The first 100 website links were categorised into UKOs/JCOs/GTPs; additional JCOs were supplemented through community experts. Websites were reviewed using customised questionnaires for BRCA information. Information provision was assessed for five domains: accessibility, scope, depth, accuracy, and quality. These domains were combined to provide a composite score (maximum score = 5). Results were screened (n = 6856) and 45 UKOs, 16 JCOs, and 18 GTPs provided BRCA information. Accessibility was high (84%,66/79). Scope was lacking with 35% (28/79) addressing >50% items. Most (82%, 65/79) described BRCA-associated cancers: breast and/or ovarian cancer was mentioned by 78%(62/79), but only 34% (27/79) mentioned ≥1 pancreatic, prostate, melanoma. Few websites provided carrier frequencies in the general (24%,19/79) and Jewish populations (20%,16/79). Only 15% (12/79) had quality information with some/minimal shortcomings. Overall information provision was low-to-moderate: median scores UKO = 2.1 (IQR = 1), JCO = 1.6 (IQR = 0.9), and GTP = 2.3 (IQR = 1) (maximum-score = 5). There is a scarcity of high-quality BRCA information online. These findings have implications for UK Jewish BRCA programmes and those considering BRCA testing.

2 September 2026 in Systematic Reviews
Verified
Journal Article
Open access
PDF file
JZJingsong Zhao
Jingsong Zhao
CFCaitlin T. Fierheller
Caitlin T. Fierheller
JAJasmine Abdy
Jasmine Abdy
Michail SiderisMichail Sideris
Michail Sideris
SQSamantha L. Quaife
Samantha L. Quaife
JWJo Waller
Jo Waller
The standard clinical genetic testing model for hereditary cancers applies stringent eligibility criteria and consistently misses large numbers of at-risk

12 September 2026 in International Journal of Gynecological Cancer
Verified
Journal Article
Open access
CFCaitlin T Fierheller
Caitlin T Fierheller
PDPriyanka Deshmukh
Priyanka Deshmukh
AKAshwin Kalra
Ashwin Kalra
HMHamda Mohamed
Hamda Mohamed
WAWythehi Ambihapathy
Wythehi Ambihapathy
DTDetect-2 Team
Detect-2 Team
Mainstreaming patients with ovarian, endometrial, and colorectal cancer in the context of genetic testing at cancer diagnosis involves pre-test counseling, consent, and return of results by the clinical cancer team. This process uses significant clinician time and resources. Alternative implementation strategies might be more cost-efficient and better utilize limited cancer health professional and genetics workforce resources, but their efficacy is less well understood. To determine if direct-to-patient genetic testing for ovarian, endometrial, and colorectal cancer has equivalent uptake of genetic testing compared with mainstreaming. Patients at ovarian, endometrial, or colorectal cancer diagnosis have equivalent uptake for genetic testing through direct-to-patient compared with mainstreaming. A multicenter randomized controlled trial evaluating a digitally enabled direct-to-patient (saliva-based, at home) genetic testing approach (intervention arm) compared with mainstreaming genetic testing (control arm). After study consent and randomization, patients in the direct-to-patient arm are offered access to an app-based decision aid, consent to genetic testing via the app, and access to a helpline for additional support and counseling if needed. Control arm participants are offered routine mainstreaming genetic testing in the clinic. We include a qualitative sub-study of 1:1 interviews to understand the attitudes, experiences, and impact on emotional well-being of patients undergoing genetic testing. Inclusion criteria include diagnosis of ovarian, endometrial, or colorectal cancer fulfilling the National Health Service clinical genetic testing criteria. Exclusion criteria include prior genetic testing for or a known familial pathogenic variant in ovarian, endometrial, or colorectal cancer susceptibility genes. Absolute difference in uptake of genetic testing between arms in the intention-to-treat population, with equivalence determined using a 10% margin based on a 2-sided 95% confidence interval. Target n = 626 to 832 patients. We will test equivalence if ≥626 patients are recruited in the intention-to-treat population. Recruitment by December 2026 and publication of results in 2028. ISRCTN:57402067 (July 26, 2023). (https://doi.org/10.1186/ISRCTN57402067).